Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-75
SponsorUniversity of Leicester

About this trial

Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood.

Aim: To determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (T2D).

Plan: 518 asymptomatic adults (aged 18-75 years) with T2D will undergo comprehensive evaluation of cardiac structure and function using cardiac MRI (CMR) and spectroscopy, echocardiography, CT coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation.

Primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. Secondary hypotheses: will assess whether CMR is more sensitive to detect early cardiac dysfunction than echocardiography and BNP, and whether cardiac dysfunction is related to peak oxygen consumption.

Expected value of results: This study will reveal the prevalence and determinants of cardiac dysfunction in T2D, and could provide targets for novel therapies.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participant is willing and able to give informed consent for participation in the study.

Male or Female, aged ≥18 and ≤75 years.

Diagnosed with Stable type 2 diabetes (determined by: i) formal diagnosis in GP case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%).

Disqualifiers

Angina pectoris or limiting dyspnoea (>NYHA II),

Major atherosclerotic disease: Symptomatic CAD, history of myocardial infarction, previous revascularisation, stroke/transient ischaemic attack or symptomatic peripheral vascular disease.

Atrial fibrillation or flutter.

Moderate or severe valvular heart disease.

Trial population

Cases will be adults with stable type 2 diabetes and no past medical history of known cardiovascular disease.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy

    Diagnostic test

    CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.

  • Transthoracic echocardiography

    Diagnostic test

    Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.

  • Computed tomography coronary artery calcium scoring

    Diagnostic test

    Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.

  • Cardiopulmonary exercise testing

    Diagnostic test

    Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.

  • Manganese-enhanced magnetic resonance imaging (MEMRI)

    Diagnostic test

    A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.

  • Ambulatory blood pressure monitoring

    Diagnostic test

    A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.

  • Accelerometer watch

    Diagnostic test

    Watch worn to collect free living physical activity data for 7 days.

  • Blood tests

    Diagnostic test

    Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.

Treatment groups

593 Participants
are divided into 2 treatment groups
Group A: Type 2 diabetics8 interventions
Group B: Healthy controls8 interventions

Trial outcomes

Primary outcomes

1

Prevalence of early heart failure in type 2 diabetes

Proportion of participants with type 2 diabetes who have features of early heart failure

Time frame
5 years

Secondary outcomes

1

Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes

Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes

Time frame
3 years
2

Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes

Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes

Time frame
3 years
3

Independent association of CMR measures with aerobic exercise capacity in type 2 diabetes

Independent association of CMR measures (LV systolic and diastolic strain and strain rates) with aerobic exercise capacity (peak VO2) in type 2 diabetes

Time frame
3 years
4

Differences in LV remodelling (indexed LV mass) between cases and controls

Differences in LV remodelling (indexed LV mass) between cases and controls

Time frame
3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.